The estimated Net Worth of Capital Managing Member Iv,... is at least $76.6 Milion dollars as of 20 November 2020. Capital Iv owns over 2,839 units of Organogenesis stock worth over $76,606,758 and over the last 5 years Capital sold ORGO stock worth over $0.
Capital has made over 7 trades of the Organogenesis stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital bought 2,839 units of ORGO stock worth $14,167 on 20 November 2020.
The largest trade Capital's ever made was buying 6,000,000 units of Organogenesis stock on 26 November 2019 worth over $30,000,000. On average, Capital trades about 1,436,094 units every 49 days since 2019. As of 20 November 2020 Capital still owns at least 29,924,515 units of Organogenesis stock.
You can see the complete history of Capital Iv stock trades at the bottom of the page.
Over the last 5 years, insiders at Organogenesis have traded over $157,938,506 worth of Organogenesis stock and bought 15,146,267 units worth $65,732,558 . The most active insiders traders include Capital Managing Member Iv,..., Alan A.Erani Albert Erani D... oraz Glenn H Wisdom Starr Nussdorf. On average, Organogenesis executives and independent directors trade stock every 24 days with the average trade being worth of $1,067,103. The most recent stock trade was executed by Patrick Bilbo on 28 March 2024, trading 152,250 units of ORGO stock currently worth $179,655.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Organogenesis executives and other stock owners filed with the SEC include: